Machine Learning Evaxion’s AI Technology Identifies Cancer Vaccine Targets Associated With Longer Progression-free… GlobeNewswire Jun 5, 2023 The clinical trial of the personalized cancer vaccine EVX-01 met its primary endpoints of safety and tolerability Positive clinical…
Machine Learning Evaxion And Pennsylvania State University Publish Preclinical Data Validating Our AI-based Viral… GlobeNewswire Apr 14, 2023 Evaxion Biotech A/S, a clinical-stage biotechnology company specializing in AI-powered immunotherapies, announces the successful publication in…
Machine Learning Evaxion Presents A New Source Of AI-derived Immunotherapeutic Targets Strongly Associated With The… GlobeNewswire Mar 23, 2023 Evaxion’s AI technology has led to the identification of new viral targets for cancer immunotherapy This potentially enables…
Machine Learning Evaxion Biotech Completes Recruitment for Phase 1/2a Clinical Trial for EVX-02 AIT News Desk Mar 7, 2022 Evaxion Biotech A/S a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, has now finalized recruitment…